Skip to main
MIST
MIST logo

MIST Stock Forecast & Price Target

MIST Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Milestone Pharmaceuticals Inc. has demonstrated a positive trajectory with its key product, etripamil, as evidenced by promising results from the Phase 2 ReVeRA study, which indicated significant improvements in symptom relief for patients, bolstered by positive patient-reported outcomes. The company has also secured FDA agreement for a streamlined Phase 3 program for the treatment of atrial fibrillation with rapid ventricular rate, suggesting a clear regulatory pathway ahead and potentially expediting commercial opportunities. Additionally, with an increased estimated market share in paroxysmal supraventricular tachycardia and a 100% probability of success for its CARDAMYST initiative, Milestone appears well-positioned for a successful commercial launch that could generate considerable shareholder value in the near term.

Bears say

Milestone Pharmaceuticals faces a challenging financial outlook due to the underappreciation of its long-term revenue potential from etripamil, projected at nearly $2 billion worldwide, contingent on regulatory approval. Despite the significant reduction in heart rate observed in patients, the current phase of clinical trials may result in near-term revenue moderation, raising concerns about the company's financial stability. The reliance on successful outcomes in ongoing trials for AFib-RVR alongside the competitive landscape of cardiovascular medications adds to the uncertainty regarding the stock's performance.

MIST has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Milestone Pharmaceuticals Inc (MIST) Forecast

Analysts have given MIST a Buy based on their latest research and market trends.

According to 6 analysts, MIST has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Milestone Pharmaceuticals Inc (MIST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.